TREATMENT

AID FOR
FeLV / FIV
INFECTIONS

LTCI HAS ARRIVED

Lymphocyte T-Cell Immunomodulator (LTCI)

LTCI Indications
LTCI is an approved treatment aid for cats infected with Feline Leukemia
Virus (FeLV) and/or Feline Immuno-deficiency Virus (FIV) and the associated
symptoms of lymphopenia, opportunistic infection, anemia, granulocytopenia,
and thrombocytopenia.

LTCI Immunopharmacology
Lymphocyte T-Cell Immune Modulator is a potent regulator of CD-4
lymphocyte production and function and increases IL-2 production in animals.

IL-2 Production Fig. 1: IL-2 Production

LTCI increases the production of IL-2. IL-2 is known
1.8 48 hr. incubation
to stimulate cytotoxic T-cell responses against viruses.
24 hr. incubation
Absorbance (450 nm)

...LTCI has been shown to

1.2
increase IL-2 production in
the Jurkat cell line (Fig. 1).
Jurkat cells are a standard 0.6
cell line used to study T-cell
signaling and leukemia.
0
1 10 100 1000
LTCI Concentration (Log)

Hematopoietic Properties Fig. 2: LTCI Stimulated Platelet Recovery

It is now accepted that T-cells
LTCI
participate in the production
500 Control
of red and white blood
cells and platelets. LTCI,
400
a T-cell immune modula-
Platelet Count

tor, has been shown to 300

increase RBC counts in
severely anemic cats and 200
increase lymphocyte counts.
100
Additionally, LTCI treatment was shown to significantly
50
increase platelet recovery in a chemotherapy induced
0 5 10 15 20
thrombocytopenia model in mice (Fig. 2).
Days Following Treatment
 LTCI Safety Data

Clients depend on safe products for their pets. Veterinarians demand

safe products for treating ill patients. LTCI has completed formal
safety testing. The homology of LTCI among mammalian species,
as well as, the absence of any observed adverse events in several
animal species, suggests that LTCI has a very low toxicity profile.

LTCI Efficacy Data

FeLV and FIV Field Trial Fig. 3: Treatment Effects of LTCI After Three Injections
LTCI has been evaluated in FeLV and FIV symptomatic
cats. In a 23 cat study, three weekly injections of LTCI 80% p=0.001
significantly increased lymphocyte counts and increased
70%
the quality of life as determined by clinical scores (Fig. 3). p=0.003
60%
Study summary available at www.IMULAN.com.
% improvement

50%
Additional efficacy studies are in progress.
40%

30%
LTCI Has Been Shown to:
20%
• Increase CD-4 lymphocyte function
10%
• Increase CD-4 lymphocyte numbers
• Increase IL-2 production 0%

• Increase red cell counts in severely anemic cats Lymphocyte Count Clinical Score

Long Term Data

The long-term benefits of treatment have not been
clinically established. However, several animals in the
field trial that received monthly or bimonthly injections
have remained symptom free for long periods. Two
patients in the trial also became negative for virus by
PCR analysis of bone marrow aspirate.
Lymphocyte T-Cell Immunomodulator has received a conditional
license from the United States Department of Agriculture.
Additional efficacy and potency studies are in progress. LTCI is
manufactured by T-Cyte Therapeutics, Inc and is exclusively
distributed by IMULAN BioTherapeutics.
LTCI Use and Monitoring
Clinical Signs:
The most important monitoring method is clinical improve - IMULAN recommends
ment. Each patient should be monitored for clinical signs the following general
associated with their infection(s) and a scoring system may treatment schedule.
be established to monitor patient progress. IMULAN has a
standard evaluation form that can be provided upon request. Month 1: Weekly injections
Month 2: Every other week
Complete Blood Counts (CBC): Month 3+: Every 4-6 weeks or as necessary
Monitoring of blood cell parameters, especially lympho -
cyte and red cell counts is recommended to evaluate the The veterinarian may have to adjust treatment
subject’s progress. CBCs may be done every 2-4 weeks schedules based on individual patient response.
for patients that have lymphopenia and/or anemia.

Company
IMULAN is Dedicated to Providing Innovative Solutions to Complex Animal Diseases
IMULAN BioTherapeutics, LLC is a privately held Our policy is to provide veterinarians access to condi -
bio-science company pioneering the development of tionally approved products for diseases where no current
precision immunomodulators for veterinary medicine. approved therapy is available. Using our technology
We are dedicated to delivering innovative immune based platforms, IMULAN is rapidly developing new, first-in
treatments for a variety of challenging and life threatening class biologics, that target fundamental aspects of disease
animal diseases. by modulating the immune response and inflammation.

IMULAN has Global Animal Health Rights to the Following Technology Platforms:
Lymphocyte T-Cell Immunomodulator (LTCI) is a poly - TCR Peptide Vaccines are small peptides that modulate
peptide that regulates lymphocyte and cytokine production. T-helper cell activity. In a variety of studies, TCR peptides
LTCI has been conditionally approved for FeLV and FIV have shown the ability to restore cell mediated immunity,
infections. normalize Th1/Th2 balance, and reduced morbidity
asso ciated with infections. Ongoing work includes feline
Immune Selective Anti-Inflammatory Derivatives (ImSAIDs)
immune mediated inflammation, canine atopic dermatitis
are peptides that modulate the immune response to
and pyoderma and canine dilated cardiomyopathy.
reduce inflammation without the side effects of steroids
and non-steroidal anti-inflammatory drugs. Ongoing work
in feline asthma and sepsis.

toll free (877) 892-9595

visit www.IMULAN.com

© 2008 IMULAN BioTherapeutics, LLC